Evommune, Inc. (NYSE:EVMN) Receives Average Recommendation of “Buy” from Brokerages

Shares of Evommune, Inc. (NYSE:EVMN) have earned a consensus recommendation of “Buy” from the seven research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $39.3333.

Several research analysts have issued reports on EVMN shares. Leerink Partnrs upgraded Evommune to a “strong-buy” rating in a report on Monday, December 1st. Evercore ISI initiated coverage on shares of Evommune in a research report on Monday, December 1st. They issued an “outperform” rating and a $40.00 price target for the company. Morgan Stanley assumed coverage on shares of Evommune in a report on Monday, December 1st. They set an “overweight” rating and a $36.00 price objective on the stock. Wall Street Zen upgraded shares of Evommune from a “sell” rating to a “hold” rating in a report on Sunday, December 14th. Finally, William Blair started coverage on shares of Evommune in a report on Monday, December 1st. They issued an “outperform” rating on the stock.

Evommune Trading Down 2.2%

Shares of NYSE EVMN opened at $17.60 on Friday. Evommune has a 12-month low of $13.89 and a 12-month high of $24.03.

Evommune (NYSE:EVMN) last announced its quarterly earnings data on Thursday, December 11th. The company reported ($8.07) earnings per share for the quarter, missing the consensus estimate of ($6.58) by ($1.49). The firm had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $10.00 million.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.